By Elizabeth Finkel MELBOURNE, AUSTRALIA—A warning letter from the U.S. Food and Drug Administration (FDA) to Australian vaccine maker CSL Biotherapies has shaken confidence in the country’s biotech superstar. The 15 June letter accuses CSL of failing to adequately investigate why its Fluvax influenza vaccine last year caused a sharply elevated rate of febrile convulsions […]
Strong dollar bleeds CSL profit
By Teresa Ooi CSL’s first-half net profit fell 19 per cent to $500 million as unfavourable currency exchange rates wiped $47m from its bottom line and the blood products manufacturer continued to face weak economic conditions in key global markets. Despite the drop in earnings, CSL will pay a dividend of 35c per share unfranked […]